GSK-111870

Study Sponsor: GSK

Study Title

A phase II, randomized, observer blind, controlled, multicenter study to assess immunogenicity and antibody persistence following vaccination with GSK's candidate combined measles, mumps, and rubella vaccine (MMR) versus M-M-R® II as a first dose, both administered subcutaneously at 12-15 months of age, concomitantly with hepatitis A vaccine (HAV), varicella vaccine (VV) and pneumococcal conjugate vaccine (PCV) but at separate sites.

Medicine or Vaccine (generic name)

Measles, Mumps, Rubella Vaccine

Sponsor Identification Number

111870

Trial Registry Identification Number(#'s)

NCT00861744 2011-005860-31

Medical Condition

Measles; Mumps; Rubella

Phase

Phase 2

Link to GSK Study Register

https://www.gsk-studyregister.com/en/trial-details/?id=111870

Link to study details on ClinicalTrials.gov (if available)

http://clinicaltrials.gov/show/NCT00861744

Link to study details on EudraCT (if available)

https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005860-31

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

Date Added to this Site

September 2015